Form 4: Puma Biotechnology Director Executes Stock Sale

Director Adrian Senderowicz acquired 27,000 restricted stock units and subsequently sold 27,000 shares of Puma Biotechnology common stock.

Summary

• Director Adrian Senderowicz acquired 27,000 shares via restricted stock unit vesting on June 11, 2026.
• The director sold 27,000 shares on June 12, 2026, at a weighted average price of $7.1967 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025.
• Following these transactions, the director maintains a direct beneficial ownership of 27,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-arranged 10b5-1 plan, which is a standard mechanism for insider liquidity.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) trading plan, indicating the sale was not based on immediate non-public information.

Negatives

• The director reduced their total beneficial ownership position by 50% from 54,000 shares to 27,000 shares.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term share price performance.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives and directors to manage personal liquidity without triggering market concerns regarding material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech directors to conduct orderly divestments.
• The transaction volume is consistent with typical director equity compensation and liquidation patterns in mid-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed at market prices.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

PBYI, Puma Biotechnology, Insider Trading, Form 4, Director Sale, Biotech